78 Results

People

  1. Giralt
    Giralt
  2. Landau
    Landau
  3. Lesokhin
    Lesokhin
  4. Scordo
    Scordo
  5. Chung
    Chung
  6. Hassoun
    Hassoun
  7. Korde
    Korde
  8. Mailankody
    Mailankody
  9. Shah
    Shah
  10. Shah
    Shah

Groups

  1. Bone Marrow Transplant (78)
  2. CTCR Scholars (78)
  3. Center for Hematologic Malignancies (78)
  4. Department of Medicine (78)
  5. Hematologic Malignancies Research (78)
  6. Hematologic Malignancies, Division of (78)
  7. Myeloma (78)
  8. Sloan Kettering Institute Postdocs (78)
  9. Survivorship Research (78)
  10. Epidemiology and Biostatistics (55)
  1. "Hematologic Malignancies Research"
  2. "Center for Hematologic Malignancies"
  3. "Alexander Lesokhin"
  4. "Michael Scordo"
Formats
  1. Meeting Abstract (65)
  2. Journal Article (10)
  3. Research Letter (2)
  4. Correspondence (1)
Groups
  1. Bone Marrow Transplant (78)
  2. CTCR Scholars (78)
  3. Center for Hematologic Malignancies (78)
  4. Department of Medicine (78)
  5. Hematologic Malignancies Research (78)
  6. Hematologic Malignancies, Division of (78)

More Groups

People
  1. Alexander Lesokhin (78)
  2. Heather Landau (78)
  3. Malin Hultcrantz (78)
  4. Michael Scordo (78)
  5. Sergio Giralt (78)
  6. David Chung (77)

More People

Years
  1. 2023 (32)
  2. 2022 (20)
  3. 2021 (9)
  4. 2020 (7)
  5. 2019 (6)
  6. 2018 (4)
Publications
  1. Blood (36)
  2. Clinical Lymphoma, Myeloma and Leukemia (22)
  3. Journal of Clinical Oncology (5)
  4. American Journal of Hematology (2)
  5. Biology of Blood and Marrow Transplantation (2)
  6. Clinical Cancer Research (2)

More Publications

Publishers
  1. American Society of Hematology (36)
  2. Elsevier Inc. (26)
  3. American Society of Clinical Oncology (5)
  4. American Association for Cancer Research (2)
  5. John Wiley & Sons, Inc. (2)
  6. Nature Publishing Group (2)

More Publishers

Results (78)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) and daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Maclachlan, K. H.; Nemirovsky, D.; Derkach, A.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • T-cell exhaustion signature predicts early relapse after autologous stem cell transplant for multiple myeloma: BMT CTN 0702 secondary immune analysis
    Meeting Abstract

    Mehanna, N.; Derkach, A.; Gasmi, B.; Anagnostou, T.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Hassoun, H.; Maclachlan, K. H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Comprehensive genomic characterization of response and resistance to daratumumab-based quadruplet induction in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Maclachlan, K. H.; Tan, C. R.; Shekarkhand, T.; Rueda, C.; Serrano, E.; Nemirovsky, D.; Derkach, A.; McPherson, A.; Diamond, B.; Ziccheddu, B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • The complex structural variant chromothripsis can be defined on targeted sequencing panels, allowing direct clinical translation in order to improve multiple myeloma prognostication
    Meeting Abstract

    Maclachlan, K. H.; Ziccheddu, B.; Tan, C.; Shekarkhand, T.; Rueda, C.; Serrano, E.; Diamond, B.; Hassoun, H.; Mailankody, S.; Shah, U. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Identifying causes of unscheduled healthcare interactions and changes to patient disposition in individuals receiving outpatient commercial bispecific antibody therapy in relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Howard, A. J.; Shekarkhand, T.; Hamadeh, I. S.; Wang, A.; Patel, D.; Tan, C.; Hultcrantz, M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A whole foods plant-based weight loss intervention improves quality of life, metabolic, microbiome and immune profile in MGUS/SMM as well as progression trajectory in a subset - the Nutrivention trial
    Meeting Abstract

    Shah, U. A.; Castro, F.; Derkach, A.; Fei, T.; Hosszu, K. K.; McAvoy, D.; DeWolf, S.; Cross, J.; Gradissimo, A.; Nwankwo, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Carfilzomib,lenalidomide and dexamethasone (KRd) as induction therapy in high-risk newly diagnosed multiple myeloma
    Meeting Abstract

    Tan, C.; Korde, N.; Derkach, A.; Hultcrantz, M.; Maclachlan, K. H.; Hassoun, H.; Mailankody, S.; Shah, U. A.; Rajeeve, S.; Patel, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Patterns of cytokine release syndrome with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
    Meeting Abstract

    Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Evaluating the effect of evolving changes in serum biomarkers on the risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Nemirovsky, D.; Maclachlan, K. H.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U. A.; Tan, C.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Stem cell utilization in the era of novel therapies for multiple myeloma
    Meeting Abstract

    Nishimura, N.; Nemirovsky, D.; Devlin, S. M.; Dahi, P. B.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Mailankody, S.; Hassoun, H.; more...
    Blood (2023)

    Fulltext@MSK | Save